Current Status and Advances in the Treatment of Carbapenem-resistant Gram-negative Bacilli with Antimicrobial Drugs
10.3870/j.issn.1004-0781.2024.10.006
- VernacularTitle:耐碳青霉烯类革兰阴性菌抗菌药物治疗现状及进展
- Author:
Qi HU
1
;
Shiyu YANG
;
Qiang LIU
;
Xiao HU
;
Xue TAO
;
Hui YI
;
Yuan BIAN
;
Enwu LONG
Author Information
1. 成都中医药大学附属医院药剂科,成都 610072
- Keywords:
Carbapenem;
Resistant;
Gram-negative bacilli;
Treatment strategies
- From:
Herald of Medicine
2024;43(10):1572-1577
- CountryChina
- Language:Chinese
-
Abstract:
With the widespread use of carbapenem antibiotics,the clinical detection rate of carbapenem-resistant Gram-negative bacilli has shown a significant increase.Carbapenem-resistant Gram-negative bacilli isolates are often extensively or fully resistant,resulting in limited antimicrobial treatment options and high morbidity and mortality rates,posing a serious public health threat.The clinical treatment of carbapenem-resistant Gram-negative bacilli includes the use of single or combination antimicrobials such as polymyxin,tigecycline,and fosfomycin.A number of new antimicrobials and therapeutic approaches are under development.The clinical management of carbapenem-resistant Gram-negative infections is severely challenged by the limited choice of antimicrobial agents.Therefore,this article reviews the current status and progress of antimicrobial treatment for carbapenem-resistant Gram-negative bacilli to providing clinical reference.
